{
  "id": "hearing-loss",
  "title": "Hearing loss",
  "lang": "en",
  "source_lang": "en",
  "summary": "Hearing loss is a partial or complete reduction in the ability to detect sound. It can be conductive, sensorineural, or mixed, and it is a leading global cause of disability.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "deafness",
    "hearing impairment"
  ],
  "generated_at": "2026-10-10",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/hearing-loss/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/hearing-loss/",
      "json": "https://aiwiki.page/zh/hearing-loss.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Hearing loss is a reduction in the ability to detect, or make sense of, sounds that a person with typical hearing can perceive. It can range from mild to profound, affect one or both ears, and develop suddenly or gradually. Sound reaches the inner ear as pressure waves, and any disruption along the path from the outer ear to the nervous system can produce it. Its causes range from earwax and middle-ear infection to genetic variants, noise, ageing, and certain medicines. Hearing loss is studied by neuroscience, genetics, epidemiology, and public-health researchers, and it is treated by audiologists, otolaryngologists, and other clinicians.\n\nHearing loss matters because of its scale and consequences. The World Health Organization counts it among the most important contributors to the global burden of disability, and its prevalence rises with age. Untreated loss can affect language development in children, schooling, employment, social participation, and quality-of-life. Research has also linked it to depression and dementia, though the mechanisms are still debated. Because access to diagnosis and devices is uneven across countries, hearing loss is also a question of health-system capacity and income-inequality.\n\nThis entry first explains how hearing is measured and how the healthy auditory system works, then classifies hearing loss by type and course. It goes on to describe conductive, sensorineural, age-related, noise-induced, and genetic causes, followed by infectious and childhood causes. It then covers global epidemiology, diagnosis, treatment and rehabilitation, emerging therapies, prevention policy, social and cultural dimensions, historical development, and open research questions."
    },
    {
      "heading": "Definition and measurement",
      "text": "Hearing loss is a reduction in auditory sensitivity, expressed clinically as elevated hearing thresholds: a sound must be presented at a higher level before it can be detected. In pure-tone audiometry, individual ears are tested with tones at specified frequencies, and the lowest reliably detected level is recorded. The American Speech-Language-Hearing Association’s 2005 guidelines define the threshold as the lowest hearing level producing responses in at least half of ascending trials, with a minimum of two responses in three presentations at that level. Routine air-conduction testing covers frequencies from 250 to 8,000 Hz, including intermediate frequencies useful for describing the pattern of loss. (asha.org)\n\nThresholds are plotted on an audiogram, with frequency in hertz on the horizontal axis and hearing level in decibels (dB HL) on the vertical axis. Frequency increases from left to right; hearing level increases downward, so points lower on the chart indicate poorer sensitivity. The HL scale uses standardized, frequency- and transducer-specific reference levels rather than a single absolute sound-pressure reference. Consequently, an audiometric value must be interpreted with its scale and calibration, not treated as interchangeable with an environmental sound-level measurement. Separate symbols record each ear and distinguish air-conduction from bone-conduction results. (asha.org)\n\nFor population classification, thresholds are commonly condensed into a four-frequency pure-tone average:\n\n\\[\\mathrm{PTA}_{4}=\\frac{T_{500}+T_{1000}+T_{2000}+T_{4000}}{4},\\]\n\nwhere \\(T_f\\) is the threshold in dB HL at frequency \\(f\\) in hertz. The better-ear value is the lower of the two ear-specific averages, not an average across both ears. This measure underlies the World Health Organization’s grading system. However, a better-ear average does not by itself describe unilateral loss or the shape of the audiogram: a person may have good hearing in one ear and substantial loss in the other, or relatively good low-frequency thresholds with poorer high-frequency thresholds. WHO therefore also identifies unilateral loss separately. (iris.who.int)\n\nThe numerical boundary between normal hearing and hearing loss has changed. Earlier WHO grading, including its 2008 scheme, classified a better-ear average of 25 dB or less as no impairment; loss began above 25 dB. The World report on hearing published in 2021 instead placed mild loss at 20 to less than 35 dB, using the same four-frequency average. WHO’s current fact sheet describes normal hearing as thresholds of 20 dB or better in both ears. Thus, the frequently cited “above 25 dB” definition belongs to older classifications and should not be presented as the unchanged current WHO criterion. (ec.europa.eu)\n\n“Disabling hearing loss” is a narrower statistical category with its own historical boundaries. WHO’s 2018 estimates used loss greater than 40 dB in the better ear for adults and greater than 30 dB for children. Current WHO wording uses greater than 35 dB in the better ear, without retaining that adult–child distinction in the definition. These changes affect comparisons of prevalence: lowering a cutoff includes people excluded under an older definition, while using either ear rather than the better ear additionally captures unilateral cases. For example, a hypothetical adult with a better-ear average of 38 dB falls below the 2018 adult disabling-loss cutoff but above the current one. Population estimates therefore require an accompanying definition specifying the frequencies averaged, the ear-selection rule, the cutoff and its exact inequality, and the age group studied. (iris.who.int)"
    },
    {
      "heading": "How the healthy auditory system works",
      "text": "The outer ear collects sound waves and directs them through the ear canal to the tympanic membrane, or eardrum. Changes in air pressure make this membrane vibrate. The vibrations pass through three linked middle-ear bones—the malleus, incus and stapes—which couple movement of the eardrum to the fluid-filled cochlea in the inner ear. This mechanical stage increases the effectiveness of sound transmission from air into cochlear fluid; it does not itself generate nerve impulses. Movement within the cochlea produces a travelling wave along the basilar membrane, the flexible structure supporting the sensory apparatus for hearing. (nidcd.nih.gov)\n\nThe cochlea separates a complex sound into its frequency components through differences in mechanical properties along the basilar membrane. High-frequency sounds produce their greatest vibration near the cochlear base, close to the middle ear, whereas low-frequency sounds peak farther towards the apex. This ordered frequency-to-position relationship is called tonotopy. A high-pitched infant’s cry and a low-pitched dog’s bark therefore stimulate different regions, although natural sounds usually contain multiple frequencies and activate broader patterns. On the basilar membrane lies the organ of Corti, containing sensory hair cells and supporting cells. Each human cochlea contains approximately 3,500 inner hair cells and 12,000 outer hair cells, with distinct roles in detecting and amplifying sound. (nidcd.nih.gov)\n\nHair cells convert mechanical movement into changes in electrical activity. Their apical surfaces carry bundles of stereocilia: microscopic projections connected by fine protein structures called tip links. Deflection of a bundle towards its taller stereocilia increases tension on these links and opens mechanically sensitive ion channels. Potassium-rich fluid surrounding the bundle supplies an inward current that changes the cell’s membrane potential. In inner hair cells, depolarization opens calcium channels, triggering release of the neurotransmitter glutamate at specialized ribbon synapses onto auditory nerve fibres. Outer hair cells instead provide an important mechanical feedback mechanism: the motor protein prestin changes their length in response to voltage changes, reinforcing weak vibrations and sharpening frequency selectivity. Thus, the cochlea is an active amplifier as well as a sensory transducer. (pmc.ncbi.nlm.nih.gov)\n\nAuditory nerve fibres convey the resulting information as action potentials. Their cell bodies lie in the spiral ganglion, and their axons form the cochlear division of the vestibulocochlear nerve, cranial nerve VIII. Signals first reach the cochlear nuclei in the brainstem, then pass through interconnected pathways involving the superior olivary complex, nuclei of the lateral lemniscus and inferior colliculus. The inferior colliculus sends major ascending projections to the medial geniculate nucleus of the thalamus, which projects to the auditory regions of the cerebral cortex. These pathways also carry descending connections, allowing higher centres to influence processing at earlier stages rather than functioning as a strictly one-way chain. (ncbi.nlm.nih.gov)\n\nThe inner ear also contains the vestibular system, which detects head movement and orientation rather than airborne sound. Its three semicircular canals sense rotation; the utricle and saccule detect linear movement and orientation relative to gravity. These organs also use hair cells, whose stereocilia bend when fluid or an overlying weighted gelatinous layer moves. Vestibular signals work with vision and information from muscles and joints to stabilize gaze and posture. Because auditory and vestibular structures occupy the same inner-ear labyrinth, some conditions affect both: Ménière’s disease, for example, can produce episodes of vertigo together with hearing loss. (health.nih.gov)"
    },
    {
      "heading": "Classification by type, degree and course",
      "text": "Type identifies the part of the auditory pathway affected. Conductive hearing loss results from impaired sound transmission through the ear canal, tympanic membrane, or middle-ear ossicles; its principal effect is to reduce the sound reaching the inner ear. Sensorineural hearing loss involves dysfunction of the cochlea or vestibulocochlear nerve and can reduce both audibility and speech clarity, so making speech louder does not necessarily make it intelligible. Mixed hearing loss combines conductive and sensorineural components in the same ear—for example, when a person with an existing sensorineural deficit develops a middle-ear infection. The distinction has clinical implications: conductive components may be amenable to medical or surgical correction, whereas sensorineural deficits commonly require hearing technologies and rehabilitation. Specific causes and treatments are considered separately. (asha.org)\n\nLaterality, symmetry, and configuration provide independent descriptions rather than additional anatomical types. Unilateral loss affects one ear, while bilateral loss affects both. Bilateral loss is symmetrical when the ears have similar degrees and frequency patterns of impairment, and asymmetrical when these differ. Configuration describes the shape of the thresholds on an audiogram: a flat pattern has approximately equal loss across frequencies, a high-frequency pattern has poorer thresholds for higher-pitched sounds, and a low-frequency pattern has poorer thresholds for lower-pitched sounds. Consequently, “bilateral hearing loss” alone does not specify whether the two ears have comparable function or which frequencies are most affected. (asha.org)\n\nDegree expresses the severity of threshold elevation, usually in decibels hearing level (dB HL). A widely used classification reproduced by the American Speech-Language-Hearing Association derives from John G. Clark’s 1981 scheme: slight loss is 16–25 dB HL, mild 26–40, moderate 41–55, moderately severe 56–70, severe 71–90, and profound 91 dB HL or greater. These categories describe hearing sensitivity, not percentages of hearing lost. Degree and configuration are complementary: a high-frequency loss can include relatively preserved low-frequency thresholds and substantially poorer high-frequency thresholds. Threshold categories also do not, by themselves, establish speech-perception ability; difficulties understanding sufficiently loud speech can accompany sensorineural loss. (asha.org)\n\nOnset and course distinguish loss present at birth, termed congenital, from acquired loss developing later. Sudden loss develops abruptly or over a short interval, progressive loss worsens over time, fluctuating loss varies between assessments, and stable loss shows no substantial change. These descriptors can be combined with type and laterality—for example, a loss may be unilateral, sensorineural, and sudden. For sudden sensorineural hearing loss, a commonly used audiometric criterion is a decline of at least 30 dB at three contiguous test frequencies within 72 hours; this specifies a particular onset pattern rather than a severity category applicable to all hearing loss. (asha.org)\n\nAuditory neuropathy describes disordered transmission from the inner ear toward the brain despite preserved outer-hair-cell function. The abnormality may involve inner hair cells, their connections with auditory neurons, or the auditory nerve itself; it therefore does not imply that every kind of cochlear hair cell functions normally. Hearing thresholds may be normal or elevated, while speech understanding is poorer than those thresholds would predict. A characteristic test pattern is preserved otoacoustic emissions, indicating outer-hair-cell activity, together with an absent or markedly abnormal auditory brainstem response. (nidcd.nih.gov)\n\nCentral hearing disorders originate in the central nervous system rather than the sound-conducting structures or cochlea. Rare cortical deafness can follow bilateral injury to auditory regions of the cerebral cortex, including strokes affecting both temporal lobes, despite preserved peripheral hearing organs. This profound failure of sound perception is distinct from central auditory processing disorder, which concerns neural processing skills such as sound localization, discrimination, temporal analysis, and perception of competing or degraded signals. Central processing deficits are therefore not simply another degree of peripheral threshold loss. (pmc.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Conductive hearing loss",
      "text": "Obstruction of the external ear canal prevents sound from reaching the tympanic membrane efficiently. Impacted cerumen (earwax) is a common reversible cause: wax normally protects and lubricates the canal and moves outward through skin migration and jaw movement, but accumulated wax can partly or completely block the passage. The American Academy of Otolaryngology–Head and Neck Surgery Foundation’s 2017 guideline update, chaired by Seth R. Schwartz, reported excessive or impacted cerumen in approximately 10% of children and 5% of adults; these figures describe wax accumulation, not the proportion with associated hearing loss. Foreign bodies produce a similar mechanical obstruction, particularly beads or beans inserted by children. Canal swelling from otitis externa can also narrow the sound pathway. Removal of an uncomplicated obstruction can reverse its conductive effect, whereas accompanying damage to the eardrum or middle-ear structures can leave persistent impairment. (entnet.org)\n\nOtitis media with effusion (OME), often called glue ear, is fluid accumulation behind the eardrum without the acute inflammatory signs characteristic of an acute middle-ear infection. It can follow an infection or occur with poor Eustachian-tube function, which disrupts middle-ear ventilation. Fluid interferes with the movement of the eardrum and ossicles, reducing sound transmission. OME is especially common in childhood: the foundation’s 2016 guideline update, chaired by Richard M. Rosenfeld, estimated that approximately 90% of children experience it by age five. This cumulative occurrence does not mean that 90% have persistent hearing impairment. Effusions often resolve spontaneously, but recurrent or persistent fluid can cause fluctuating hearing difficulty. The 2023 NICE guideline identifies mishearing, difficulty listening in groups, and delayed speech and language development among its possible presentations. (entnet.org)\n\nTympanic membrane perforation can follow trauma, infection, or severe Eustachian-tube dysfunction. A perforation reduces the acoustic pressure difference across the membrane and therefore its effectiveness in driving the ossicular chain. The hearing deficit depends on more than whether a hole is present. In a 2006 prospective study, Ritvik P. Mehta and colleagues examined 62 ears from 56 patients with perforations but no other middle-ear disease. Air–bone gaps—the difference between air-conduction and bone-conduction hearing thresholds—were greatest at low frequencies and increased with perforation size. Ears with smaller middle-ear air-space volumes had mean gaps 10–20 dB larger than those with larger volumes. Anterior and posterior perforations did not differ significantly, showing why location alone is an inadequate predictor of the resulting loss. (enthealth.org)\n\nDamage to the ossicular chain introduces a separate transmission failure. Trauma can disrupt the connections between the malleus, incus, and stapes; chronic middle-ear infection can damage the eardrum and ossicles together. Cholesteatoma, an abnormal accumulation of skin within the middle ear, can grow and erode these bones. The resulting discontinuity interrupts the mechanical linkage that carries eardrum vibration to the inner ear. Conversely, an ossicle that becomes fixed cannot move adequately even if the chain remains anatomically continuous. These structural lesions differ from transient canal blockage or effusion because clearing the canal or resolving the fluid does not necessarily restore the damaged transmission mechanism. (enthealth.org)\n\nOtosclerosis causes abnormal bone remodelling that commonly fixes the stapes, limiting its vibration and the transfer of sound into the inner ear. Hearing loss usually develops gradually, may first be noticed for low-pitched sounds, and can begin in one ear before affecting the other. Congenital structural causes instead reflect abnormal formation of the outer or middle ear: aural atresia leaves the external canal absent or closed, while stenosis makes it abnormally narrow. These canal defects can accompany microtia, an underdeveloped external ear, and prevent sound from reaching the eardrum normally. Both stapes fixation and congenital canal obstruction can therefore produce conductive impairment without requiring primary damage to cochlear hair cells. (nidcd.nih.gov)"
    },
    {
      "heading": "Sensorineural hearing loss: cochlear and neural origins",
      "text": "Damage to cochlear hair cells and their stereocilia—the microscopic projections that detect mechanical movement—is a principal mechanism of sensorineural hearing loss. Bending of stereocilia normally opens ion channels, initiating the electrical response to sound; disruption of the bundle can impair this conversion even before the cell dies. Outer hair cells amplify sound-induced vibrations within the cochlea, whereas inner hair cells provide sensory input to the auditory nerve. Damage therefore has different consequences depending on which cells and connections are affected: loss of outer hair-cell function reduces cochlear amplification, while inner hair-cell or nerve damage compromises the transmission of sound information. (nidcd.nih.gov)\n\nThe persistence of cochlear damage reflects the limited regenerative capacity of the mammalian inner ear. Mature human cochlear hair cells do not naturally replace themselves after destruction, unlike the sensory hair cells of birds and some other vertebrates. Hearing loss caused by their death is consequently generally permanent. This does not mean that every sensorineural threshold change represents irreversible cell loss: sudden hearing loss can recover partly or completely, and some inner-ear disorders produce fluctuating function. Ageing, excessive noise and certain medications can damage the same sensory-cell population, although their exposure patterns and additional mechanisms differ. (nidcd.nih.gov)\n\nNeural injury can also impair hearing without equivalent destruction of outer hair cells. Relevant sites include the synapses between inner hair cells and auditory nerve fibres, the auditory neurons, and the nerve itself. Auditory neuropathy illustrates this distinction: outer hair-cell activity may remain detectable while neural transmission is markedly abnormal. Speech understanding can be substantially poorer than the measured sound-detection thresholds would suggest; a person may detect a voice yet have difficulty recognising its words. Thus, the sensory and neural components of sensorineural loss are related but not interchangeable, and the degree of audibility loss does not fully describe the disruption of auditory information. (nidcd.nih.gov)\n\nSudden sensorineural hearing loss develops abruptly or over hours to a few days, usually in one ear. A commonly used audiometric criterion is a deterioration of at least 30 decibels across three consecutive test frequencies within 72 hours. Associated symptoms may include ear fullness, tinnitus and dizziness. The US National Institute on Deafness and Other Communication Disorders reports that only about 10% of diagnosed cases have an identifiable cause. Proposed explanations for otherwise unexplained cases include viral infection and disturbances of blood circulation; recognised associated disorders include autoimmune disease and neurological disease. These possibilities do not establish a single mechanism for idiopathic cases. Approximately half of affected people recover some or all hearing spontaneously, usually within one to two weeks, distinguishing this presentation from established loss caused by destruction of hair cells. (nidcd.nih.gov)\n\nMénière’s disease has a different, episodic course, combining fluctuating hearing loss with vertigo, tinnitus and ear fullness. The 2020 clinical practice guideline describes documented low- to mid-frequency sensorineural loss and spontaneous vertigo attacks lasting 20 minutes to 12 hours. Its symptoms are associated with endolymphatic hydrops, an abnormal buildup of fluid within the membranous labyrinth that disrupts hearing and balance signalling. The underlying cause of this fluid disturbance remains incompletely understood. Hearing can vary between episodes rather than following a uniformly progressive pattern, and the disorder usually affects one ear, although the NIDCD reports bilateral involvement in 15–25% of affected people. (pubmed.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Age-related hearing loss",
      "text": "Age-related hearing loss, or presbycusis, typically develops gradually in both ears, with broadly similar severity on the two sides. It is predominantly sensorineural and usually affects high frequencies first, producing a downward-sloping audiogram rather than an equal reduction in sensitivity across all pitches. The World Health Organization (WHO) described this bilateral, high-frequency pattern in its 2015 World report on ageing and health. Because deterioration is slow, affected people may not initially recognize the change. Difficulty following conversation, particularly against competing sound, can become apparent before everyday sounds seem substantially quieter. Age-related changes involve both the inner ear and the neural pathways that process sound. (who.int)\n\nThe prevalence of hearing loss rises sharply in later adulthood, although estimates depend on the severity threshold used. WHO’s 2021 World report on hearing estimated that moderate-or-greater hearing loss affected 15.4% of people aged 60–69 globally, increasing to 58.2% among those aged 90 and above; more than 42% of people with hearing loss of any degree were older than 60. The report identified age-related hearing loss as the greatest source of societal and economic burden from hearing loss across the life course. These age-group figures describe hearing loss in older populations, not cases proven to result exclusively from biological ageing. In the United States, NIDCD calculations using 2015–2020 National Health and Nutrition Examination Survey data found disabling hearing loss in 22% of adults aged 65–74 and 55% of those aged 75 or older, using a threshold of at least 35 decibels in the better ear. (iris.who.int)\n\nPresbycusis does not correspond to a single microscopic lesion. Sensory hair-cell degeneration, loss of auditory neurons, and changes in the stria vascularis—the cochlear tissue that maintains the electrical conditions needed for sound transduction—can coexist. Their relative contributions have been reassessed as tissue measurements have improved. In a 2020 human temporal-bone study, Pei-Zhe Wu and colleagues found that hair-cell loss explained hearing-threshold elevations better than strial atrophy, challenging the view that deterioration of the cochlea’s metabolic “battery” is generally the dominant cause. Their findings also indicated that an audiogram’s shape alone cannot reliably identify the underlying tissue pathology. (pmc.ncbi.nlm.nih.gov)\n\nSeveral processes can contribute to this degeneration. Lifetime noise exposure adds sensory damage, while high blood pressure and diabetes mellitus are associated with hearing loss in older adults; medications toxic to the inner ear can further complicate the clinical picture. These associations do not establish one universal vascular or metabolic mechanism. (nidcd.nih.gov) Experimental evidence also implicates oxidative stress and mitochondrial cell-death pathways. In 2009, Shinichi Someya and colleagues showed that deleting the pro-apoptotic Bak gene in C57BL/6J mice reduced age-related death of cochlear hair cells and spiral-ganglion neurons and prevented hearing deterioration in that model. This provides evidence for a specific biological pathway in mice, rather than proof that the same pathway accounts for all human presbycusis. (pubmed.ncbi.nlm.nih.gov)\n\nGenetic susceptibility helps explain why people with comparable ages and exposure histories can have different hearing trajectories. A 2019 study led by Helena R. R. Wells, involving more than 250,000 UK Biobank participants aged 40–69, identified 44 independent genomic associations with self-reported adult hearing difficulty. Its questionnaire-based phenotype also illustrates a measurement limitation: reported difficulty, hearing-aid use, and measured pure-tone thresholds are not interchangeable outcomes. (pmc.ncbi.nlm.nih.gov) Separating ageing from environmental injury is therefore difficult: long-term noise exposure, chronic disease, and ototoxic medication use accumulate alongside age, and several causes can affect the same ear. Older age is a strong population-level predictor of hearing loss, but neither age nor a high-frequency audiogram specifies how much of an individual’s impairment arose from intrinsic ageing rather than lifetime exposures. (nidcd.nih.gov)"
    },
    {
      "heading": "Noise exposure and ototoxicity",
      "text": "Noise-induced hearing loss depends on sound level, exposure duration, and repeated exposure, rather than on whether the sound is experienced as unpleasant. Sources include industrial machinery, woodworking tools, firearms, concerts, and personal audio devices played at high volume. Much of the permanent damage results from injury and death of cochlear hair cells, which do not naturally regenerate in humans. Repeated exposure may produce gradually worsening hearing and difficulty understanding speech. In 1998, the United States National Institute for Occupational Safety and Health established a recommended occupational exposure limit of 85 A-weighted decibels (dBA), averaged over eight hours, with a 3-dB exchange rate: equivalent daily doses are reached at 88 dBA over four hours or 91 dBA over two hours. This is an occupational risk-management benchmark, not a boundary below which every individual is protected or a general limit for recreational listening. (nidcd.nih.gov)\n\nA single intense impulse, such as a nearby gunshot or explosion, can cause immediate and permanent acoustic injury. Besides damaging the cochlea, a blast can rupture the tympanic membrane or injure the middle-ear bones, adding a conductive component to the loss. Less severe noise exposure can cause a temporary threshold shift: hearing becomes muffled and then appears to recover, commonly within 16–48 hours. Such recovery does not necessarily exclude residual injury. The distinction between temporary and permanent effects therefore concerns the subsequent hearing threshold, not simply the duration or apparent severity of the initial symptoms. (nidcd.nih.gov)\n\nOtotoxicity is injury to hearing or balance structures caused by particular substances, including some medications. Aminoglycoside antibiotics, such as gentamicin, can cause both auditory and vestibular toxicity, with aminoglycoside-related hearing loss generally irreversible. Gentamicin-associated loss initially affects high frequencies and may not be recognized during ordinary conversation. Its prescribing information identifies impaired kidney function, excessive doses, and prolonged treatment as important risk factors. Reduced renal clearance allows the drug to remain longer in the body and accumulate in serum and tissues; auditory or balance abnormalities may sometimes become apparent only after treatment has ended. (dailymed.nlm.nih.gov)\n\nPlatinum-based chemotherapy, particularly cisplatin, is another established cause of permanent hearing loss. A 2017 study by Andrew M. Breglio, Lisa L. Cunningham, and colleagues investigated why cochlear exposure differs from exposure in other organs. Using mass spectrometry in mice and postmortem human tissue, the researchers found prolonged retention of platinum in the cochlea, including at least 18 months after the last chemotherapy cycle in a human specimen. Accumulation was particularly marked in the stria vascularis, which maintains the ionic composition of cochlear fluid. In the mouse experiments, cisplatin reduced the endocochlear electrical potential and impaired outer-hair-cell function, demonstrating that toxicity involves the physiological support of hearing as well as sensory-cell injury. (nature.com)\n\nLoop diuretics differ from aminoglycosides and cisplatin in that reported hearing impairment may be reversible or irreversible. Furosemide prescribing information associates ototoxicity with rapid injection, severe renal impairment, higher-than-recommended doses, low blood-protein concentrations, and concurrent exposure to other ototoxic drugs. Combining furosemide with an aminoglycoside can enhance toxicity; the gentamicin label notes that intravenous diuretics may alter antibiotic concentrations in serum and tissues. Drug-related risk thus depends on administration and interacting exposures, not merely on the presence of a medication in an ototoxic drug class. (dailymed.nlm.nih.gov)\n\nTinnitus—the perception of sound without an external sound source—commonly accompanies noise-related injury and can also occur with ototoxic medication exposure. It may be described as ringing, buzzing, hissing, or roaring, in one or both ears. Noise-associated tinnitus can resolve or persist, while medication-associated tinnitus is linked to certain antibiotics, anticancer drugs, and other agents, especially at high doses. Tinnitus is a symptom distinct from a raised hearing threshold: hearing loss is strongly associated with it, but not everyone with hearing loss develops tinnitus. Its occurrence alone does not establish the cause or permanence of auditory damage. (nidcd.nih.gov)"
    },
    {
      "heading": "Genetic and congenital hearing loss",
      "text": "Congenital hearing loss is present at birth, whereas prelingual hearing loss develops before spoken-language acquisition; neither term necessarily implies a genetic cause. Conversely, genetically determined hearing loss can first appear in childhood or adulthood. Genetic causes account for at least half of childhood hearing loss in developed countries, although estimates vary with the population and cases included. Congenital infections and perinatal complications constitute separate, non-genetic causes. Approximately 70% of prelingual genetic hearing loss is nonsyndromic, meaning that hearing loss occurs without associated abnormalities in other organ systems; the remainder is syndromic. This distinction can change as a child grows, because some accompanying features emerge later than the hearing impairment. (pmc.ncbi.nlm.nih.gov)\n\nAbout 80% of nonsyndromic genetic cases follow autosomal recessive inheritance: pathogenic variants affect both copies of a gene, usually with one inherited from each parent. Parents carrying only one affected allele generally have normal hearing, so an affected child may have no apparent family history. When both parents carry a pathogenic variant in the same recessive hearing-loss gene, each pregnancy has a 25% probability of an affected child, a 50% probability of an unaffected carrier, and a 25% probability of an unaffected non-carrier. Autosomal dominant forms account for approximately 19% of nonsyndromic genetic cases and often produce postlingual, progressive loss; one affected gene copy is sufficient. X-linked and mitochondrial forms are uncommon. X-linked variants cannot pass from father to son, while mitochondrial variants are transmitted maternally and may affect children of either sex. (ncbi.nlm.nih.gov)\n\nThe affected proteins participate in several distinct cochlear processes. GJB2 encodes connexin 26, which forms gap-junction channels between neighbouring cells; biallelic pathogenic variants are a common cause of congenital nonsyndromic sensorineural loss, with severity ranging from mild to profound. Their contribution varies substantially between populations. OTOF encodes otoferlin, a calcium-sensitive protein required for neurotransmitter release at the synapses connecting inner hair cells to auditory nerve fibres. Defective otoferlin therefore interrupts sound-signal transmission rather than simply destroying hair cells. In typical OTOF-related loss, otoacoustic emissions can initially remain detectable despite severe-to-profound hearing impairment and abnormal auditory brainstem responses. This explains why screening based only on otoacoustic emissions can miss this genetic form. (ncbi.nlm.nih.gov)\n\nUsher syndrome combines sensorineural hearing loss with retinitis pigmentosa, a progressive degeneration of retinal photoreceptors; some forms also impair vestibular function. Type I usually involves profound congenital hearing loss and balance difficulties, whereas type II generally involves moderate-to-severe congenital loss with retinal symptoms appearing later. Genes include MYO7A, CDH23 and USH2A, and inheritance is autosomal recessive. CHARGE syndrome, associated with pathogenic variants in CHD7, affects embryonic development across multiple systems. Its characteristic abnormalities include ocular coloboma, heart defects, blockage of the posterior nasal passages, and external or internal ear abnormalities. The CHD7 protein participates in chromatin remodelling and regulation of gene expression, illustrating how a developmental genetic disorder can affect hearing alongside other organs. (medlineplus.gov)\n\nGenetic testing can establish an aetiological diagnosis, clarify inheritance, and distinguish isolated hearing loss from a syndrome whose additional manifestations are not yet apparent. Multigene panels and exome or genome sequencing address the considerable genetic heterogeneity; interpretation combines laboratory findings with hearing characteristics and family history. In a 2016 study led by Christina M. Sloan-Heggen, comprehensive testing of 1,119 patients identified a genetic cause in 440, or 39%, involving 49 genes. Large copy-number changes accounted for 18% of the pathogenic variants, demonstrating the importance of detecting deletions and duplications as well as sequence changes. Genetic counselling uses an established molecular diagnosis to explain recurrence probabilities and possible disease course. Nevertheless, relatives with the same pathogenic variants may differ in severity or age of onset, and a negative test does not exclude a genetic cause. (pubmed.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Infections, perinatal and childhood causes",
      "text": "Intrauterine infection can produce hearing loss even when no hereditary disorder is present. Rubella virus can infect the placenta and fetus during pregnancy, causing congenital rubella syndrome, whose characteristic abnormalities include hearing impairment, cataracts and congenital heart disease. The risk of fetal abnormalities is highest when maternal infection occurs during the first 12 weeks of gestation. Hearing impairment may be the infant’s only recognized manifestation, rather than part of an obvious multisystem syndrome. Australian ophthalmologist Norman Gregg first recognized the association between maternal rubella and congenital cataracts in 1941, following a 1940 epidemic; subsequent investigation established the wider congenital syndrome. This prenatal mechanism differs from hearing loss acquired through infections after birth. (archive.cdc.gov)\n\nCytomegalovirus (CMV) is another important infectious cause of congenital sensorineural hearing loss. CDC estimates indicate that approximately one in 200 babies in the United States is born with congenital CMV; about one in five affected infants develops birth defects or other long-term health problems, a category that includes—but is not limited to—hearing loss. Hearing loss can occur in children without other symptoms at birth, affect one or both ears, and emerge or progress after a normal newborn hearing screen. Deterioration may occur during the first two years and sometimes continue into adolescence. Congenital infection is distinguished from infection acquired after birth by detecting viral DNA in samples collected within the first three weeks of life; later detection alone cannot establish prenatal acquisition. (cdc.gov)\n\nChronic suppurative otitis media is characterized by persistent discharge from the middle ear through a perforated tympanic membrane. It is an important cause of preventable childhood hearing impairment, particularly in resource-constrained settings. Unlike uncomplicated middle-ear effusion, it combines persistent infection with structural damage to the sound-transmission apparatus. A 2004 World Health Organization report estimated that 65–330 million people worldwide had discharging ears attributable to this condition and that approximately 60% had significant hearing impairment. These historical estimates covered all ages, not children alone, and their wide range reflected differences in disease definitions and survey methods. WHO also identifies chronic nonsuppurative middle-ear fluid as a separate childhood cause; its conductive mechanism is discussed in the section on conductive hearing loss. (iris.who.int)\n\nBacterial meningitis can cause severe or profound sensorineural loss, with cochlear inflammation followed by fibrosis and ossification. New bone formation within the cochlea can also complicate subsequent cochlear implantation. In a 2012 retrospective study of 34 implant candidates with bilateral profound postmeningitic hearing loss, cochlear ossification was identified in 35% of patients by computed tomography and 44% by magnetic resonance imaging; these figures describe a selected severely affected group, not all meningitis survivors. Childhood measles and mumps are additional infectious causes. Mumps-associated hearing impairment may be transient or permanent; CDC surveillance guidance records permanent unilateral deafness in approximately one in 20,000 infected people in the prevaccine era. Measles, mumps and rubella are vaccine-preventable, while rubella’s principal hearing-related consequence is prenatal rather than an ordinary complication of childhood infection. (pmc.ncbi.nlm.nih.gov)\n\nPerinatal risk factors include prematurity, low birth weight, oxygen deprivation at birth and severe neonatal hyperbilirubinemia. Premature or critically ill infants may have several overlapping exposures, so prematurity is not necessarily an isolated causal explanation. The Joint Committee on Infant Hearing’s 2019 statement identifies neonatal intensive-care stays exceeding five days, hypoxic–ischemic encephalopathy and hyperbilirubinemia requiring exchange transfusion as risk indicators. Severe jaundice can disrupt auditory neural function even when outer cochlear hair-cell responses remain present. In a 2016 prospective study by Sanjiv B. Amin and colleagues, five of 44 late-preterm or term infants with severe jaundice developed auditory neuropathy spectrum disorder; peak unbound bilirubin, rather than total serum bilirubin, was associated with the abnormality. Ordinary mild neonatal jaundice is therefore not equivalent to the severe hyperbilirubinemia represented in these risk criteria. (who.int)"
    },
    {
      "heading": "Epidemiology and global burden",
      "text": "The World Health Organization (WHO) estimated in 2018 that 466 million people had disabling hearing loss, including approximately 432 million adults and 34 million children. That estimate used thresholds exceeding 40 dB in the better-hearing ear for adults aged 15 years or older and 30 dB for children. Later WHO statements cite approximately 430 million people requiring rehabilitation, using a disabling-loss threshold exceeding 35 dB in the better-hearing ear. These figures belong to different estimation frameworks; their numerical difference should not be interpreted as evidence that global prevalence declined between reporting dates. (studylib.net)\n\nThe Global Burden of Disease Study (GBD) 2019 hearing-loss analysis, published in 2021, estimated that 1.57 billion people—20.3% of the global population—had hearing loss, with a 95% uncertainty interval of 1.51–1.64 billion. Approximately 1.17 billion had mild loss, illustrating why counts of all hearing loss greatly exceed counts restricted to disabling loss. The estimate for moderate-to-complete loss was 430.4 million before adjustment for hearing-aid use and 403.3 million after adjustment. These were modelled population estimates rather than a worldwide census: the investigation assembled 215 survey sources from 77 countries, with 113 sources from 54 countries informing prevalence modelling. (pmc.ncbi.nlm.nih.gov)\n\nThe burden is unevenly distributed by age, sex and geography. In GBD 2019, 62.1% of people with hearing loss were older than 50 years; the Western Pacific had the largest number with moderate-to-complete loss, approximately 127.1 million. WHO’s 2018 estimates counted 242 million adult males and 190 million adult females with disabling loss. Higher male prevalence also appears in age-standardised national estimates: the GBD analysis for the United States reported rates of 17.7% in males and 11.8% in females in 2019. WHO estimates that nearly 80% of people with disabling loss live in low- and middle-income countries, where the concentration of cases coincides with substantial gaps in hearing-care provision. (doi.org)\n\nGBD 2019 attributed 43.45 million years lived with disability (YLDs) to hearing loss. YLDs weight time lived with a condition by its severity, distinguishing non-fatal health burden from simple case counts. The category “age-related and other hearing loss” ranked third among global causes of YLDs and first among people older than 70 years. The study’s Healthcare Access and Quality Index explained 65.8% of variation in national age-standardised YLD rates, with poorer access associated with higher burden. This association does not establish that access alone causes differences in prevalence, but incorporates the importance of low hearing-aid coverage in determining unaddressed disability. (pmc.ncbi.nlm.nih.gov)\n\nWHO’s 2021 World report on hearing projected nearly 2.5 billion people with some degree of hearing loss by 2050, including more than 700 million with disabling loss requiring rehabilitation; its March 2026 fact sheet retains these projections. Population growth and ageing are major drivers: increasing case numbers can occur even when age-standardised prevalence remains stable. The economic burden extends beyond clinical expenditure. WHO estimates that unaddressed hearing loss costs approximately US$980 billion annually, encompassing health-sector costs excluding hearing devices, educational support, lost productivity and societal costs. This monetary estimate measures a different dimension of burden from either prevalence or YLDs. (who.int)"
    },
    {
      "heading": "Diagnosis and assessment",
      "text": "Clinical diagnosis combines a history of onset, progression, noise and medication exposure, family history, and communication difficulties with ear examination and audiological testing. Otoscopy identifies obstructing wax, foreign bodies, and abnormalities of the ear canal or tympanic membrane before measurements are interpreted. Pure-tone audiometry establishes frequency-specific thresholds separately for each ear. The American Speech-Language-Hearing Association’s 2005 guidelines specify routine air-conduction testing from 250 to 8,000 Hz and bone-conduction measurements principally from 250 to 4,000 Hz. Comparing these routes helps distinguish impaired sound transmission from cochlear or neural loss: an air–bone gap indicates a conductive component. When sound could cross to the opposite ear, masking noise is presented to that ear to obtain ear-specific results. (asha.org)\n\nSpeech audiometry measures abilities that an audiogram alone does not describe. A speech-recognition threshold is the level at which approximately half the presented speech material is correctly identified and provides a cross-check against pure-tone thresholds. Word-recognition testing measures the proportion of words understood at levels above threshold, whereas speech-in-noise testing assesses understanding against competing sound. These measures distinguish sound detection from intelligibility and document difficulties that may be less apparent during conversation in quiet. Test selection takes account of language, vocabulary, and developmental abilities; children may identify pictures rather than repeat words. Recorded materials provide greater standardization between sessions than live-voice presentation. (asha.org)\n\nTympanometry measures the acoustic response of the middle-ear system while air pressure in the ear canal is varied. A normally positioned peak indicates that maximum sound transmission occurs near atmospheric pressure. A flat, type B tracing can accompany middle-ear fluid or tympanic membrane perforation; a negatively displaced, type C peak indicates negative middle-ear pressure. These patterns are interpreted alongside otoscopy rather than treated as stand-alone diagnoses. Acoustic reflex testing records changes in middle-ear acoustic admittance caused by sound-evoked muscle contraction. Testing with stimulation and recording on the same or opposite sides contributes information about middle-ear function and the integrity of the reflex pathway. (asha.org)\n\nBehavioural methods are adapted to developmental age. Visual reinforcement audiometry, commonly used at approximately 6–24 months, rewards a conditioned head turn with an illuminated toy or video. Conditioned play audiometry, usually suitable at developmental ages of 2–4 years, links hearing a tone to an action such as placing a block in a bucket. Objective measurements complement these responses. Otoacoustic emissions are cochlear-generated sounds recorded in the ear canal and principally assess outer hair-cell function; outer- or middle-ear obstruction can also prevent their detection. The auditory brainstem response (ABR) records sound-evoked neural activity through surface electrodes. Frequency-specific stimuli, commonly at 500, 1,000, 2,000, and 4,000 Hz, permit threshold estimation in infants and others unable to provide reliable behavioural responses. ABR estimates require appropriate correction and behavioural confirmation when feasible. (asha.org)\n\nAsymmetry, sudden onset, unilateral tinnitus, vertigo, and neurological signs influence further investigation. The United Kingdom’s 2018 NICE guideline identifies unexplained hearing loss developing within three days and occurring within the preceding 30 days as requiring specialist assessment within 24 hours. Magnetic resonance imaging of the internal auditory canals investigates suspected retrocochlear disease, including vestibular schwannoma. NICE specifies localizing signs such as facial weakness as an indication regardless of hearing thresholds, and an interaural difference of at least 15 dB at two adjacent frequencies as a criterion for considering imaging in otherwise non-localizing sensorineural loss. Assessment also documents tinnitus, recurrent or unresolved balance symptoms, and their functional effects, which may require investigations beyond routine audiometry. (nice.org.uk)"
    },
    {
      "heading": "Treatment and rehabilitation",
      "text": "Treatment of conductive hearing loss can restore sound transmission when the obstruction or middle-ear abnormality is reversible. Impacted earwax may be removed by microsuction, irrigation or manual extraction. Antibiotics treat selected ear infections rather than hearing loss itself; uncomplicated acute otitis media often resolves without them. Persistent middle-ear effusion is managed differently: ventilation tubes, also called grommets, provide an opening through the eardrum to ventilate the middle ear, while hearing devices offer a nonsurgical alternative. Ossiculoplasty reconstructs a damaged ossicular chain, sometimes replacing one or more bones with a prosthesis to improve transmission to the inner ear. (nice.org.uk)\n\nHearing aids provide acoustic amplification for sensorineural loss when sufficient cochlear function remains. A microphone converts sound into electrical signals, an amplifier increases their strength, and a receiver delivers amplified sound into the ear. Surviving hair cells convert the increased vibration into neural signals; amplification therefore has limits when cochlear damage is extensive. Prescription devices are programmed for the individual’s hearing loss, and directional microphones and noise-reduction settings can assist listening in background noise. Two aids are commonly fitted when both ears have aidable loss. In the United States, the over-the-counter category took effect on October 17, 2022, allowing adults aged 18 or older with perceived mild-to-moderate loss to buy hearing aids without a prescription or professional fitting. This category does not cover children or severe-to-profound loss. (nidcd.nih.gov)\n\nCochlear implants use electrical rather than acoustic stimulation to provide auditory information to people with severe-to-profound loss. An external microphone and speech processor encode sound; a transmitter communicates with an implanted receiver–stimulator, which sends impulses to an electrode array in the cochlea. These impulses bypass damaged sensory structures and stimulate the auditory nerve. The resulting percept is not normal hearing and requires learning or relearning through auditory rehabilitation. Outcomes vary between recipients. For children, earlier implantation followed by intensive therapy can support language acquisition during early development; since 2020, US approvals have included eligible children beginning at nine months of age. Audiologists and speech-language pathologists participate in developing recognition of environmental sounds and speech after implantation. (nidcd.nih.gov)\n\nOther implanted devices retain mechanical stimulation of the cochlea. Bone-anchored hearing systems transmit vibration through the skull, bypassing the outer and middle ear, and are used for selected middle-ear disorders or unilateral deafness. Active middle-ear implants instead use a transducer to move an ossicle directly, strengthening vibration entering the inner ear. These devices differ fundamentally from cochlear implants: their output remains mechanical rather than direct electrical stimulation of the auditory nerve. (nidcd.nih.gov)\n\nBimodal hearing combines a cochlear implant in one ear with a hearing aid in the other. A randomized controlled trial published in March 2026 by Yeliz Jakobsen and colleagues included 63 adults with asymmetric loss who met cochlear-implant candidacy criteria in one ear. Compared with optimally fitted replacement hearing aids, bimodal use improved the signal-to-noise ratio required for 70% correct speech reception by 10.26 dB. Word-recognition scores improved by approximately 18.6 percentage points in quiet and 18.2 points in noise. These findings concern a selected implant-candidate population, rather than all people with asymmetric loss. (pubmed.ncbi.nlm.nih.gov)\n\nRehabilitation also addresses device handling and communication needs. NICE’s adult guideline specifies follow-up 6–12 weeks after hearing-aid fitting, with checks of comfort, sound quality, volume, microphone settings, cleaning and telephone use. Fine-tuning and maintenance support accompany evaluation of whether the device meets the person’s communication goals. Assistive listening devices and communication strategies may be used alongside, or instead of, hearing aids, with follow-up to assess their effectiveness. (nice.org.uk)"
    },
    {
      "heading": "Emerging research and therapies",
      "text": "Gene therapy for OTOF-related deafness targets defective transmission between inner hair cells and the auditory nerve rather than replacing lost sensory cells. OTOF encodes otoferlin, a protein involved in the release of neurotransmitter at hair-cell synapses. The investigational treatment DB-OTO uses two adeno-associated virus vectors to reconstruct a functional OTOF expression cassette, with a hair-cell-specific promoter restricting expression to the intended cells. Administration is by infusion into the cochlea. A clinical report published online in October 2025 described improved hearing in treated children, including normalization of hearing sensitivity in three of twelve participants. This approach addresses a particular molecular defect; its results do not establish efficacy for noise-induced or age-related hearing loss. (pmc.ncbi.nlm.nih.gov)\n\nOn April 23, 2026, the United States Food and Drug Administration granted accelerated approval to lunsotogene parvec-cwha, marketed as Otarmeni and developed as DB-OTO. Its indication covers children and adults with molecularly confirmed biallelic OTOF variants, severe-to-profound or profound sensorineural loss meeting the specified threshold, preserved outer hair-cell function, and no previous cochlear implant in the treated ear. The supporting ongoing, single-arm trial included 24 children aged ten months to sixteen years; 80% of the twenty participants evaluable for efficacy experienced improved hearing. Continued approval is contingent on further assessment of durability and verification of effects on speech development and quality of life. Reported adverse effects included middle-ear infection, nausea, dizziness, and procedural pain. (fda.gov)\n\nHair-cell regeneration research instead seeks to convert cochlear supporting cells into sensory cells. One strategy increases activity of ATOH1, a transcription factor required for hair-cell differentiation, either through gene delivery or by inhibiting developmental signalling pathways that suppress this cell fate. The REGAIN trial tested LY3056480, a small-molecule gamma-secretase inhibitor intended to inhibit Notch signalling and thereby promote regeneration. Led by Anne G. M. Schilder, its phase I component enrolled fifteen adults and its phase IIa component forty-four adults with mild-to-moderate sensorineural loss. Participants received three intratympanic injections over two weeks. Results published in 2024 showed that treatment was tolerated but did not restore hearing across the study group, illustrating the distinction between inducing regenerative pathways experimentally and demonstrating functional benefit in humans. (pmc.ncbi.nlm.nih.gov)\n\nOtoprotective drugs aim to prevent injury rather than reverse established loss. In the SIOPEL 6 randomized controlled trial, published in 2018, children with standard-risk hepatoblastoma received cisplatin with or without sodium thiosulfate, administered six hours after the cisplatin infusion. Hearing loss occurred in eighteen of fifty-five evaluable children receiving sodium thiosulfate, compared with twenty-nine of forty-six receiving cisplatin alone: 33% versus 63%, with a relative risk of 0.52. Delayed administration was intended to preserve otoprotection while limiting interference with cisplatin’s antitumour action. On September 20, 2022, the FDA approved the formulation Pedmark for reducing cisplatin-associated ototoxicity in children aged at least one month with localized, non-metastatic solid tumours. (nejm.org)\n\nResearch in hearing-aid signal processing uses machine learning to distinguish speech from competing noise and adjust processing accordingly. A 2025 study of a commercial deep-neural-network algorithm in twenty participants found modest improvements on three speech-in-noise tests, including approximately 1 dB on QuickSIN and the Words-in-Noise test, but no significant improvement on a nonsense-syllable test using speech-shaped noise. Benefits varied between listeners; the study received manufacturer funding. (public-pages-files-2025.frontiersin.org) Meanwhile, organoids grown from pluripotent stem cells provide experimental models of inner-ear development. In 2023, Stephen T. Moore, Eri Hashino, and colleagues reported human cochlear organoids containing cells with structural and functional characteristics consistent with inner and outer hair cells. These culture systems provide tools for studying cochlear differentiation and disease mechanisms; generating such cells in vitro is distinct from establishing a transplantation treatment. (scholarworks.indianapolis.iu.edu)"
    },
    {
      "heading": "Prevention and public health policy",
      "text": "The World Health Organization (WHO) coordinates World Hearing Day on 3 March each year, providing evidence-based campaign materials for governments, health services and civil-society organizations. Its World Report on Hearing, published in 2021 following World Health Assembly resolution WHA70.13 of 2017, established a framework for integrated, people-centred ear and hearing care within national health plans. This links prevention, identification and rehabilitation rather than treating them as separate services, with particular attention to countries where service capacity does not match need. The report places hearing care within strengthened health systems and promotes delivery through primary health care. WHO estimated in 2021 that nearly 60% of childhood hearing loss could be prevented through measures including immunization against rubella and meningitis, improved maternal and neonatal care, and early management of middle-ear disease. (who.int)\n\nOccupational prevention combines exposure measurement, noise reduction and continuing hearing surveillance. In the United States, the National Institute for Occupational Safety and Health recommends an eight-hour average exposure limit of 85 A-weighted decibels (dBA), using a 3-dB exchange rate: every 3-dB increase halves the corresponding exposure duration. Thus, 88 dBA corresponds to four hours and 91 dBA to two hours. This health-based recommendation differs from the Occupational Safety and Health Administration’s general-industry permissible exposure limit of 90 dBA over eight hours, calculated with a 5-dB exchange rate. OSHA requires a hearing-conservation programme at an eight-hour average of 85 dBA, including exposure monitoring, audiometric testing, training and hearing protection. Prevention policies prioritize eliminating or reducing noise at its source and engineering or administrative controls; earplugs and earmuffs supplement these measures rather than replacing effective noise control. (cdc.gov)\n\nFor recreational exposure, safe-listening standards address both sound intensity and accumulated listening time. The 2019 WHO–International Telecommunication Union standard for personal audio devices specifies reference weekly sound allowances equivalent to 80 dB for 40 hours for adults and 75 dB for 40 hours for children. It proposes software that estimates exposure dose from level and duration, displays the proportion of the allowance used, and supports automatic volume reduction and parental controls. WHO’s 2022 standard for venues and events extends prevention to amplified-music environments: its six features include a maximum average sound level of 100 decibels, calibrated monitoring and recording, optimized acoustics, audience hearing protection, quiet zones, and staff training. These are technical recommendations for reducing risk, distinct from enforceable national workplace regulations. (who.int)\n\nNewborn hearing screening is an early-identification intervention, not a means of preventing congenital hearing loss itself. The United States Early Hearing Detection and Intervention framework uses “1–3–6” benchmarks: screening by one month of age, diagnostic evaluation by three months for infants who do not pass, and enrolment in early intervention by six months. Its purpose is to limit delays in communication and language acquisition, including spoken and signed language. Screening coverage alone is therefore an incomplete measure of programme performance. CDC reported that, in 2019, 27.5% of US infants who did not pass screening were lost to follow-up or documentation, compared with 51.1% in Texas. The distinction matters: loss to follow-up denotes services not received, whereas loss to documentation may reflect care received but not reported. Referral coordination and reporting systems are consequently integral components of screening policy. (cdc.gov)\n\nScaling these services is constrained by workforce shortages, affordability and uneven geographical distribution. WHO’s 2021 report found that approximately 78% of low-income countries had fewer than one ear, nose and throat specialist per million people, and 93% had fewer than one audiologist per million. Globally, it estimated that only 17% of people who could benefit from hearing aids used them. Proposed policy mechanisms include training primary-care personnel, sharing tasks with specialists, and integrating referral pathways into routine services. WHO’s economic modelling estimated that expansion of hearing-care interventions required an additional annual investment of US$1.33 per person and could produce nearly US$16 in benefits for each dollar invested over ten years; these were projected returns, not measured outcomes of completed programmes. (who.int)"
    },
    {
      "heading": "Social, educational and cultural dimensions",
      "text": "Communication access shapes participation in education, employment and public life. Spoken instruction, workplace discussions and information delivered without captions or interpretation can exclude people who cannot reliably hear speech. Accessibility measures address different barriers: captions provide a written representation of speech, sign-language interpreters provide linguistic access for signers, and assistive listening systems transmit a speaker’s voice more directly to a listener’s device. These supports complement rather than simply duplicate amplification. The World Health Organization identifies communication restrictions, stigma and limited educational and employment access among the consequences of unaddressed hearing loss. A concrete employment disparity was documented by the US National Deaf Center’s 2019 report: in 2017, 53.3% of deaf adults aged 25–64 were employed, compared with 75.8% of hearing adults—a gap of 22.5 percentage points. This population comparison does not establish hearing loss as the sole cause of the difference. (who.int)\n\nFor children, reduced access to language during early development can affect vocabulary, grammar and subsequent literacy, with consequences for academic attainment. The relevant distinction is between hearing ability and access to an intelligible language: language acquisition can proceed through spoken or signed language, whereas inadequate access to either creates developmental risks. In a 1998 study, Christine Yoshinaga-Itano and colleagues compared 72 children whose hearing loss was identified by six months of age with 78 identified later; both groups received intervention, on average, within two months of identification. The earlier-identified group had significantly better receptive and expressive language scores. Among children with normal cognitive abilities, the association extended across communication modes, degrees of hearing loss and socioeconomic strata. This observational finding supported early identification and intervention without demonstrating that identification alone determined later achievement. (who.int)\n\nHearing loss is also associated with social isolation, loneliness and depression. Difficulty following conversation can restrict everyday interaction, while embarrassment or stigma can contribute to withdrawal. Its association with cognitive decline and dementia has prompted investigation of mechanisms including effortful listening, in which decoding degraded speech draws on cognitive resources, and reduced social and sensory stimulation. These remain proposed explanations rather than a complete causal account. The 2023 ACHIEVE randomized controlled trial, led by Frank Lin and colleagues, enrolled 977 adults aged 70–84 with untreated hearing loss. Hearing aids and audiological support did not significantly reduce three-year cognitive decline in the combined study population. A prespecified analysis of the 238 participants recruited from the Atherosclerosis Risk in Communities cohort, who had greater baseline risk, found 48% less cognitive decline with the intervention; no benefit was detected in the healthier volunteer cohort. The outcome concerned cognitive change, not demonstrated prevention of dementia. (cdn.who.int)\n\nDeaf culture provides a linguistic and cultural framework distinct from a solely medical description of impaired hearing. Sign-language communities share languages, social practices and identities; membership is not adequately described by an audiometric threshold alone. Sign languages are natural languages with their own grammatical structures, not universal gesture systems or word-for-word renderings of speech. American Sign Language, for example, differs grammatically from English and is distinct from British Sign Language. Family language environments are especially consequential: the US National Institute on Deafness and Other Communication Disorders reports that nine out of ten children born deaf have hearing parents, who may initially have no experience with a signed language. Deaf peers and other fluent signers can therefore become important language models. (stacks.cdc.gov)\n\nDebate over childhood cochlear implantation concerns language access and cultural belonging as well as auditory outcomes. The clinical rationale emphasizes access to sound during early language development; early implantation followed by intensive support can facilitate spoken-language acquisition, although outcomes vary. Deaf advocacy perspectives emphasize that implantation should not displace access to sign language or Deaf communities. The National Association of the Deaf’s 2023 position statement on language deprivation advocates early access to visual language and rejects presenting spoken and signed languages as mutually exclusive choices. These positions differ in emphasis: a device’s capacity to support speech does not itself resolve questions about accessible family communication, educational language or cultural participation. (nidcd.nih.gov)"
    },
    {
      "heading": "History of understanding and treatment",
      "text": "Ear trumpets were in use by the seventeenth century and became more common in the eighteenth century, long before electrical amplification. Their horn-shaped openings collected sound and directed it through a narrower tube into the ear; they required neither a microphone nor a power supply. Designs ranged from conspicuous handheld horns to collapsible instruments: the Wellcome Collection preserves a Victorian folding tin trumpet made by Atkinson of Holborn, London. Eighteenth-century users included the painter Joshua Reynolds and the geologist James Hutton. These devices increased access to conversation but depended on their acoustic shape and positioning rather than electronically adjustable amplification. (melnickmedicalmuseum.com)\n\nTelephone technology enabled the transition to electrical hearing aids in the late nineteenth century. Early systems combined carbon microphones, batteries and ear receivers; initially bulky tabletop instruments, they developed into clothing-worn devices around 1902. Vacuum-tube amplification subsequently provided greater power, although separate batteries and body-worn components limited portability. The replacement of tubes by transistors in the early 1950s reduced size and power requirements. Acousticon’s transistorized A330, introduced in 1953, sold for $74.50. Unlike vacuum tubes, transistors did not require a warm-up period or a separate battery for heating, making compact, portable amplification more practical. (melnickmedicalmuseum.com)\n\nQuantitative audiometry developed alongside these technologies, replacing judgments based chiefly on conversational speech or other comparatively variable test sounds with measurements at controlled frequencies and intensities. Western Electric’s 1-A audiometer was presented to American specialist societies in 1922; the otologist Edmund Prince Fowler contributed to its design. It generated 20 selectable tones across a range of 32–16,384 Hz, with adjustable intensity, allowing frequency-specific hearing thresholds to be plotted. Fowler and Ralph Wegel also presented the audiogram chart that year. This pairing of a controlled sound generator with a graphical record helped establish hearing loss as a measurable pattern across frequencies rather than a single undifferentiated deficit. (americanhistory.si.edu)\n\nExperimental electrical stimulation opened a different route from acoustic amplification. In 1957, André Djourno and Charles Eyriès elicited auditory sensations by electrically stimulating the auditory nerve in a deaf patient. William House and neurosurgeon John Doyle undertook intracochlear electrode experiments in 1961; House subsequently developed a single-channel device implanted in 1972. Multichannel cochlear implants sought to convey more spectral information by stimulating different positions along the cochlea through separate electrodes. Graeme Clark began relevant research in 1967, and his Melbourne team implanted its multichannel prototype in 1978. Clinical trials and commercialization followed in the 1980s; the US Food and Drug Administration approved the Nucleus multichannel system on October 31, 1985. These implants bypassed damaged sensory structures rather than restoring ordinary acoustic hearing. (pmc.ncbi.nlm.nih.gov)\n\nDigital signal processing became commercially established in hearing aids during the 1990s. A significant turning point was the 1996 introduction of Widex’s Senso, followed by Oticon’s DigiFocus. Earlier digitally programmable instruments still processed sound through analog circuitry; fully digital devices converted the microphone signal into numerical samples for processing. Their development depended particularly on reducing chip size and power consumption enough for wearable use. Software-controlled frequency shaping and multichannel compression then allowed amplification to be adjusted more precisely, while subsequent processing architectures enabled more elaborate feedback and noise-control algorithms. (journals.sagepub.com)\n\nOrganized early detection and international policy also expanded the field beyond individual devices. A US National Institutes of Health consensus conference in March 1993 recommended universal newborn hearing screening. NIDCD’s 1997 workshop identified auditory brainstem responses and evoked otoacoustic emissions as suitable physiological methods and emphasized that screening required linked diagnostic and intervention services. Internationally, the World Health Organization developed its 2021 World report on hearing in response to World Health Assembly resolution WHA70.13, adopted in 2017. The report placed integrated, people-centred ear and hearing care within national health planning and universal health coverage, formalizing a broader public-health approach alongside clinical assessment and rehabilitation. (nidcd.nih.gov)"
    },
    {
      "heading": "Open questions and research debates",
      "text": "Hidden hearing loss describes listening difficulties, particularly impaired speech understanding in noise, despite normal conventional pure-tone thresholds. Whether it constitutes a distinct disorder, and how often it occurs, remain unsettled. One proposed mechanism is cochlear synaptopathy: loss of synapses connecting inner hair cells to auditory nerve fibres without corresponding hair-cell loss. In 2009, Sharon Kujawa and M. Charles Liberman demonstrated in mice that noise exposure could cause lasting synaptic damage and subsequent nerve degeneration even after hearing thresholds recovered. Translation to human diagnosis is less straightforward. A 2018 study by Hannah Guest and colleagues found neither reduced auditory brainstem response amplitudes nor greater reported lifetime noise exposure in participants with impaired speech-in-noise performance and normal audiograms. Such negative findings do not exclude synaptopathy, because the electrophysiological measures may lack sensitivity, but they challenge its use as a general explanation for these complaints. Without a validated, sufficiently specific biomarker, estimates of hidden hearing loss cannot reliably distinguish synaptic injury from other sources of listening difficulty. (pubmed.ncbi.nlm.nih.gov)\n\nRegeneration research faces a distinction between producing new sensory cells and restoring useful hearing. In animal experiments, inhibition of Notch signalling can increase expression of the developmental regulator Atoh1, inducing supporting cells to become hair cells. However, the REGAIN trial, published in 2024, illustrates the difficulty of translating this mechanism into clinical benefit. Its phase IIa component enrolled 44 adults with mild-to-moderate sensorineural loss, who received three middle-ear injections of the gamma-secretase inhibitor LY3056480. The study did not meet its primary efficacy endpoint: improvement in average hearing thresholds at 2, 4 and 8 kHz after 12 weeks. Individual improvements did not establish group-level efficacy or demonstrate regeneration anatomically. Whether newly generated human hair cells can acquire appropriate function and connections—and whether auditory nerve fibres can be repaired sufficiently to improve everyday communication—remains distinct from demonstrating regenerative activity in laboratory models. (discovery.ucl.ac.uk)\n\nDifferences in prevalence estimates partly concern what is counted rather than competing measurements of an identical condition. The Global Burden of Disease 2019 analysis estimated 1.57 billion people with hearing loss, using a better-ear threshold of at least 20 dB averaged across 0.5, 1, 2 and 4 kHz; approximately 430 million had moderate-to-complete loss, defined as at least 35 dB. The World Health Organization’s 2021 figures drew on this same analysis, so WHO and GBD numbers are not necessarily independent estimates. GBD excluded self-reported hearing data and used statistical modelling to combine population studies and estimate unobserved populations. National surveys may instead measure perceived hearing difficulty, restrict participation to particular ages, or use different thresholds. Comparisons also depend on whether rates are age-standardized: GBD found a substantial increase in affected population counts between 1990 and 2019 alongside broadly stable age-standardized prevalence. (pmc.ncbi.nlm.nih.gov)\n\nThe mechanisms of tinnitus and idiopathic sudden sensorineural hearing loss remain incompletely resolved. Tinnitus research examines altered auditory signalling and interactions with brain networks governing attention and emotion; hearing loss alone does not explain why only some affected individuals develop tinnitus. Treatments that reduce distress therefore do not necessarily eliminate its perceptual generator. For sudden loss, proposed mechanisms include disrupted cochlear blood flow and inflammation, but an identifiable cause is uncommon. Steven Rauch and colleagues’ 2011 randomized trial of 250 patients found intratympanic corticosteroids noninferior to oral corticosteroids. Because it compared two active treatments rather than treatment against placebo, it addressed delivery route rather than establishing how much recovery steroids produced beyond spontaneous improvement. (nidcd.nih.gov)\n\nAccess research concerns sustainable service delivery as well as device prices. WHO’s 2024 guidance estimated that only 17% of more than 400 million people who could benefit from hearing aids used them. Its proposed task-sharing approaches assign selected assessment, fitting and maintenance responsibilities to trained nonspecialists, with separate pathways for adults and children aged five years or older. Outstanding implementation questions include how health systems finance continuing care, maintain specialist referral capacity and address stigma alongside shortages of trained personnel. Lower-cost devices alone do not resolve the need for fitting, maintenance and sustained support. (who.int)"
    }
  ],
  "links": [
    "pressure",
    "nervous-system",
    "neuroscience",
    "genetics",
    "epidemiology",
    "public-health",
    "world-health-organization",
    "disability",
    "quality-of-life",
    "depression",
    "dementia",
    "health-system",
    "income-inequality",
    "prevalence",
    "ion-channel",
    "membrane-potential",
    "neurotransmitter",
    "synapse",
    "action-potential",
    "central-nervous-system",
    "otitis-media",
    "language-acquisition",
    "neuron",
    "autoimmune-disease",
    "diabetes-mellitus",
    "gene",
    "ion",
    "tinnitus",
    "allele",
    "pregnancy",
    "measles",
    "productivity",
    "diagnosis",
    "electrode",
    "randomized-controlled-trial",
    "gene-therapy",
    "signal-processing",
    "machine-learning",
    "primary-health-care",
    "sign-language",
    "education",
    "literacy",
    "universal-health-coverage",
    "biomarker",
    "inflammation"
  ],
  "sources": [
    {
      "title": "Guidelines for Manual Pure-Tone Threshold Audiometry",
      "url": "https://www.asha.org/policy/GL2005-00014/"
    },
    {
      "title": "Audiometric Symbols",
      "url": "https://www.asha.org/policy/gl1990-00006/"
    },
    {
      "title": "PRIMARY EAR AND HEARING CARE",
      "url": "https://iris.who.int/bitstream/handle/10665/366334/9789240069152-eng.pdf"
    },
    {
      "title": "Type, Degree, and Configuration of Hearing Loss",
      "url": "https://www.asha.org/siteassets/ais/ais-type-degree-and-configuration-of-hearing-loss.pdf"
    },
    {
      "title": "Personal Music Players & Hearing: 4. In what ways can hearing be impaired?",
      "url": "https://ec.europa.eu/health/scientific_committees/opinions_layman/en/hearing-loss-personal-music-player-mp3/l-2/4-hearing-impairement.htm"
    },
    {
      "title": "WORLD REPORT",
      "url": "https://iris.who.int/bitstream/handle/10665/339913/9789240020481-eng.pdf"
    },
    {
      "title": "Deafness and hearing loss",
      "url": "https://www.who.int/en/news-room/fact-sheets/detail/deafness-and-hearing-loss"
    },
    {
      "title": "Addressing the rising prevalence of hearing loss",
      "url": "https://iris.who.int/bitstream/handle/10665/260336/9789241550260-eng.pdf"
    },
    {
      "title": "How Do We Hear?",
      "url": "https://www.nidcd.nih.gov/health/how-do-we-hear"
    },
    {
      "title": "Information about Hearing, Communication, and Understanding - NIH Curriculum Supplement Series",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK20366/?report=reader"
    },
    {
      "title": "Hair cell transduction, tuning and synaptic transmission in the mammalian cochlea",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5658794/"
    },
    {
      "title": "Sensory processing of sound by inner hair cells of the cochlea",
      "url": "https://pubchem.ncbi.nlm.nih.gov/pathway/Reactome%3AR-HSA-9662360"
    },
    {
      "title": "Auditory Pathway - StatPearls",
      "url": "https://www.ncbi.nlm.nih.gov/sites/books/NBK532311/?report=reader"
    },
    {
      "title": "Identifying Neuron Types and Circuit Mechanisms in the Auditory Midbrain",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11000261/"
    },
    {
      "title": "Balance Disorders",
      "url": "https://health.nih.gov/health-topics-a-z/balance-disorders"
    },
    {
      "title": "Balance Disorders — Causes, Types & Treatment",
      "url": "https://www.nidcd.nih.gov/health/balance-disorders"
    },
    {
      "title": "Hearing Loss in Adults",
      "url": "https://www.asha.org/practice-portal/clinical-topics/hearing-loss/"
    },
    {
      "title": "Sudden Sensorineural Hearing Loss (SSHL) | NIDCD",
      "url": "https://www.nidcd.nih.gov/health/sudden-deafness"
    },
    {
      "title": "What Is Auditory Neuropathy? — Causes & Treatment | NIDCD",
      "url": "https://www.nidcd.nih.gov/health/auditory-neuropathy"
    },
    {
      "title": "Cortical Deafness Due to Ischaemic Strokes in Both Temporal Lobes",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8311059/"
    },
    {
      "title": "Central Auditory Processing Disorder",
      "url": "https://www.asha.org/practice-portal/clinical-topics/central-auditory-processing-disorder"
    },
    {
      "title": "Experts Update Best Practices for Diagnosis and Treatment of Earwax (Cerumen Impaction) Important Patient Education on Healthy Ear Care",
      "url": "https://www.entnet.org/resource/aao-hnsf-updated-cpg-earwax-press-release/"
    },
    {
      "title": "Conductive Hearing Loss - ENT Health",
      "url": "https://www.enthealth.org/conditions/conductive-hearing-loss/"
    },
    {
      "title": "AAO-HNSF Updated Clinical Practice Guideline: Otitis Media with Effusion – Press Release & Fact Sheet",
      "url": "https://www.entnet.org/resource/aao-hnsf-updated-cpg-ome-press-release-fact-sheet/"
    },
    {
      "title": "Recommendations: Otitis media with effusion in under 12s",
      "url": "https://www.nice.org.uk/guidance/ng233/chapter/Recommendations"
    },
    {
      "title": "Determinants of Hearing Loss in Perforations of the Tympanic Membrane",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2918411/"
    },
    {
      "title": "What Is Otosclerosis? Symptoms & Diagnosis",
      "url": "https://www.nidcd.nih.gov/health/otosclerosis"
    },
    {
      "title": "Anotia/Microtia",
      "url": "https://www.cdc.gov/birth-defects/about/anotia-microtia.html"
    },
    {
      "title": "Noise-Induced Hearing Loss (NIHL)",
      "url": "https://www.nidcd.nih.gov/health/noise-induced-hearing-loss"
    },
    {
      "title": "Progress Toward Hair Cell Regeneration and the Restoration of Hearing",
      "url": "https://www.nidcd.nih.gov/news/events/june-28-beyond-lab-speaker-series-progress-toward-hair-cell-regeneration-restoration-hearing"
    },
    {
      "title": "Clinical Practice Guideline: Ménière's Disease",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32267799/"
    },
    {
      "title": "Ménière’s Disease",
      "url": "https://www.nidcd.nih.gov/health/menieres-disease"
    },
    {
      "title": "World report on ageing and health",
      "url": "https://www.who.int/docs/default-source/mca-documents/ageing/9789240694811-eng.pdf?Status=Master&sfvrsn=d71aa836_2"
    },
    {
      "title": "Age-Related Hearing Loss (Presbycusis)",
      "url": "https://www.nidcd.nih.gov/health/age-related-hearing-loss"
    },
    {
      "title": "Quick Statistics About Hearing, Balance, & Dizziness",
      "url": "https://www.nidcd.nih.gov/health/statistics/quick-statistics-hearing?device=c"
    },
    {
      "title": "Age-Related Hearing Loss Is Dominated by Damage to Inner Ear Sensory Cells, Not the Cellular Battery That Powers Them",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7424870/"
    },
    {
      "title": "Age-related hearing loss in C57BL/6J mice is mediated by Bak-dependent mitochondrial apoptosis",
      "url": "https://pubmed.ncbi.nlm.nih.gov/19901338/"
    },
    {
      "title": "GWAS Identifies 44 Independent Associated Genomic Loci for Self-Reported Adult Hearing Difficulty in UK Biobank",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6817556/"
    },
    {
      "title": "Noise-Induced Hearing Loss (NIHL) | NIDCD",
      "url": "https://www.nidcd.nih.gov/health/noise-induced-hearing-loss?act=1187"
    },
    {
      "title": "Understanding Noise Exposure Limits: Occupational vs. General Environmental Noise",
      "url": "https://www.cdc.gov/niosh/bulletin/2016/noise.html"
    },
    {
      "title": "Gentamicin Injection, USP",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=60ca1487-392d-4721-aa45-3de38722896c"
    },
    {
      "title": "Cisplatin is retained in the cochlea indefinitely following chemotherapy",
      "url": "https://www.nature.com/articles/s41467-017-01837-1"
    },
    {
      "title": "DailyMed — FUROSEMIDE injection, solution",
      "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71b48f4d-9936-448c-9e3a-33f1182e1039"
    },
    {
      "title": "What Is Tinnitus? — Causes and Treatment",
      "url": "https://www.nidcd.nih.gov/health/tinnitus"
    },
    {
      "title": "The Epidemiology of Deafness",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/6719589/"
    },
    {
      "title": "Genetic Hearing Loss Overview - GeneReviews®",
      "url": "https://ncbi.nlm.nih.gov/books/NBK1434/"
    },
    {
      "title": "Nonsyndromic hearing loss: MedlinePlus Genetics",
      "url": "https://medlineplus.gov/genetics/condition/nonsyndromic-hearing-loss/"
    },
    {
      "title": "GJB2-Related Autosomal Recessive Nonsyndromic Hearing Loss - GeneReviews®",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK1272/?report=classic"
    },
    {
      "title": "OTOF-Related Hearing Loss - GeneReviews®",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK1251/"
    },
    {
      "title": "Usher syndrome: MedlinePlus Genetics",
      "url": "https://medlineplus.gov/genetics/condition/usher-syndrome/"
    },
    {
      "title": "Usher Syndrome Type II - GeneReviews®",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK1341/"
    },
    {
      "title": "CHD7 gene: MedlinePlus Genetics",
      "url": "https://medlineplus.gov/genetics/gene/chd7/"
    },
    {
      "title": "Comprehensive genetic testing in the clinical evaluation of 1119 patients with hearing loss",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26969326/"
    },
    {
      "title": "1 Congenital Rubella Syndrome (CRS)",
      "url": "https://archive.cdc.gov/www_cdc_gov/ncbddd/birthdefects/surveillancemanual/chapters/chapter-5/chapter5-1.html"
    },
    {
      "title": "Chapter 15: Congenital Rubella Syndrome",
      "url": "https://www.cdc.gov/surv-manual/php/table-of-contents/chapter-15-congenital-rubella-syndrome.html"
    },
    {
      "title": "Congenital CMV and Hearing Loss",
      "url": "https://www.cdc.gov/cytomegalovirus/media/pdfs/2024/08/print-2018-cmv-hearing-fact-sheet-7b-508_updated-2024.pdf"
    },
    {
      "title": "Congenital CMV and Hearing Loss",
      "url": "https://www.cdc.gov/cytomegalovirus/congenital-infection/hearing-loss.html"
    },
    {
      "title": "Clinical Overview of CMV and Congenital CMV",
      "url": "https://www.cdc.gov/cytomegalovirus/hcp/clinical-overview/index.html"
    },
    {
      "title": "Chronic suppurative otitis media",
      "url": "https://iris.who.int/bitstream/handle/10665/42941/9241591587.pdf"
    },
    {
      "title": "Hearing Loss in Bacterial Meningitis Revisited—Evolution and Recovery",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9985150/"
    },
    {
      "title": "Cochlear ossification in patients with profound hearing loss following bacterial meningitis",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22497482/"
    },
    {
      "title": "Childhood hearing loss: strategies for prevention and care",
      "url": "https://www.who.int/docs/default-source/imported2/childhood-hearing-loss--strategies-for-prevention-and-care.pdf?sfvrsn=cbbbb3cc_0"
    },
    {
      "title": "Chapter 9: Mumps",
      "url": "https://www.cdc.gov/surv-manual/php/table-of-contents/chapter-9-mumps.html"
    },
    {
      "title": "JCIH 2019",
      "url": "https://www.audiology.org/wp-content/uploads/2021/06/JCIH-2019.pdf"
    },
    {
      "title": "Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7960691/"
    },
    {
      "title": "Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019",
      "url": "https://doi.org/10.1016/S0140-6736%2821%2900516-X"
    },
    {
      "title": "Hearing Loss Prevalence, Years Lived With Disability, and Hearing Aid Use in the United States From 1990 to 2019: Findings From the Global Burden of Disease Study",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10718207/"
    },
    {
      "title": "WHO: 1 in 4 people projected to have hearing problems by 2050",
      "url": "https://www.who.int/news/item/02-03-2021-who-1-in-4-people-projected-to-have-hearing-problems-by-2050"
    },
    {
      "title": "Deafness and hearing loss",
      "url": "https://www.who.int/health-topics/hearing-loss?trk=public_post_comment-text"
    },
    {
      "title": "Determining Threshold Level for Speech",
      "url": "https://www.asha.org/policy/gl1988-00008/"
    },
    {
      "title": "Hearing Loss in Children",
      "url": "https://www.asha.org/practice-portal/clinical-topics/hearing-loss-in-children/"
    },
    {
      "title": "Hearing Loss in Adults",
      "url": "https://www.asha.org/practice-portal/clinical-topics/hearing-loss"
    },
    {
      "title": "Recommendations: Hearing loss in adults: assessment and management",
      "url": "https://www.nice.org.uk/guidance/ng98/chapter/recommendations"
    },
    {
      "title": "NG98 Hearing loss in adults: assessment and management: Full guideline 2018",
      "url": "https://www.nice.org.uk/guidance/ng98/evidence/full-guideline-pdf-4852693117"
    },
    {
      "title": "Summary of the evidence | Otitis media (acute): antimicrobial prescribing",
      "url": "https://www.nice.org.uk/guidance/NG91/chapter/summary-of-the-evidence"
    },
    {
      "title": "Glue ear - NHS",
      "url": "https://www.nhs.uk/conditions/glue-ear/"
    },
    {
      "title": "Ossiculoplasty",
      "url": "https://www.royalberkshire.nhs.uk/media/wbalzmg1/ossiculoplasty_jun25.pdf"
    },
    {
      "title": "Hearing Aids — Styles/Types & How They Work | NIDCD",
      "url": "https://www.nidcd.nih.gov/health/hearing-aids"
    },
    {
      "title": "Recommendations | Hearing loss in adults: assessment and management",
      "url": "https://www.nice.org.uk/guidance/NG98/chapter/recommendations"
    },
    {
      "title": "OTC Hearing Aids: What You Should Know | FDA",
      "url": "https://www.fda.gov/medical-devices/hearing-aids/otc-hearing-aids-what-you-should-know?trk=article-ssr-frontend-pulse_little-text-block"
    },
    {
      "title": "What Are Cochlear Implants for Hearing? | NIDCD",
      "url": "https://www.nidcd.nih.gov/health/cochlear-implants?_sp=f114d839-4a60-4493-be40-88ad1200a4e4"
    },
    {
      "title": "Benefits of cochlear implant and hearing aid in a bimodal solution compared to optimally fitted new hearing aids in patients with asymmetric hearing loss: a randomised controlled trial",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41818424/"
    },
    {
      "title": "Functional, sustained recovery of hearing in Otoferlin-deficient mice using DB-OTO, a hair-cell-specific AAV-based gene therapy",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12481892/"
    },
    {
      "title": "FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program",
      "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-ever-gene-therapy-treatment-genetic-hearing-loss-under-national-priority-voucher"
    },
    {
      "title": "A phase I/IIa safety and efficacy trial of intratympanic gamma-secretase inhibitor as a regenerative drug treatment for sensorineural hearing loss",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10907343/"
    },
    {
      "title": "UCL and UCLH successfully complete world-first trial of a regenerative hearing drug",
      "url": "https://www.uclhospitals.brc.nihr.ac.uk/news/ucl-and-uclh-successfully-complete-world-first-trial-regenerative-hearing-drug"
    },
    {
      "title": "FDA approves sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors",
      "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sodium-thiosulfate-reduce-risk-ototoxicity-associated-cisplatin-pediatric-patients"
    },
    {
      "title": "Effectiveness of deep neural networks in hearing aids for improving signal-to-noise ratio, speech recognition, and listener preference in background noise",
      "url": "https://public-pages-files-2025.frontiersin.org/journals/audiology-and-otology/articles/10.3389/fauot.2025.1677482/pdf"
    },
    {
      "title": "Generating high-fidelity cochlear organoids from human pluripotent stem cells",
      "url": "https://scholarworks.indianapolis.iu.edu/items/74989180-fe33-4cc3-ba9a-3196320d0d65"
    },
    {
      "title": "Generating high-fidelity cochlear organoids from human pluripotent stem cells",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10695300/"
    },
    {
      "title": "World Hearing Day",
      "url": "https://www.who.int/campaigns/world-hearing-day"
    },
    {
      "title": "World report on hearing",
      "url": "https://www.who.int/publications/i/item/9789240020481?trk=article-ssr-frontend-pulse_little-text-block"
    },
    {
      "title": "Noise-Induced Hearing Loss",
      "url": "https://www.cdc.gov/niosh/noise/about/noise.html?CDC_AAref_Val=https%3A%2F%2Fwww.cdc.gov%2Fniosh%2Ftopics%2Fnoise%2Fnoise.html"
    },
    {
      "title": "Occupational Noise Exposure - Overview",
      "url": "https://www.osha.gov/noise"
    },
    {
      "title": "95 - Occupational noise exposure.",
      "url": "https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.95"
    },
    {
      "title": "Provide Hearing Protection",
      "url": "https://www.cdc.gov/niosh/noise/prevent/ppe.html"
    },
    {
      "title": "Safe listening devices and systems: a WHO-ITU standard",
      "url": "https://www.who.int/publications/i/item/9789241515276"
    },
    {
      "title": "WHO releases new standard to tackle rising threat of hearing loss",
      "url": "https://www.who.int/news/item/02-03-2022-who-releases-new-standard-to-tackle-rising-threat-of-hearing-loss"
    },
    {
      "title": "WHO global standard for safe listening venues and events",
      "url": "https://www.who.int/publications-detail-redirect/9789240043114"
    },
    {
      "title": "Infants with Suspected Hearing Loss May Not Receive Timely Diagnosis or Early Intervention",
      "url": "https://www.cdc.gov/hearing-loss-children/articles/infants-suspected-hearing-loss.html"
    },
    {
      "title": "World Report on Hearing: Executive Summary",
      "url": "https://cdn.who.int/media/docs/default-source/documents/health-topics/deafness-and-hearing-loss/world-report-on-hearing/wrh-executive-summary.en.pdf?download=true&sfvrsn=feb8d533_30"
    },
    {
      "title": "Assistive Devices for People with Hearing or Speech Disorders",
      "url": "https://www.nidcd.nih.gov/health/assistive-devices-people-hearing-voice-speech-or-language-disorders"
    },
    {
      "title": "Employment Report Shows Strong Labor Market Passing by Deaf Americans",
      "url": "https://nationaldeafcenter.org/news-items/employment-report-shows-strong-labor-market-passing-deaf-americans/?nocache=1"
    },
    {
      "title": "Childhood hearing loss: strategies for prevention and care",
      "url": "https://www.who.int/docs/default-source/imported2/childhood-hearing-loss--strategies-for-prevention-and-care.pdf"
    },
    {
      "title": "American Sign Language",
      "url": "https://www.nidcd.nih.gov/health/american-sign-language"
    },
    {
      "title": "Language of early- and later-identified children with hearing loss",
      "url": "https://pubmed.ncbi.nlm.nih.gov/9794949/"
    },
    {
      "title": "Why should you care?",
      "url": "https://cdn.who.int/media/docs/default-source/ncds/sdr/deafness-and-hearing-loss/ehc-brochure-en.pdf?download=true&sfvrsn=c609e5ef_6"
    },
    {
      "title": "Take care of your senses: The science behind sensory loss and dementia risk",
      "url": "https://www.nia.nih.gov/news/take-care-your-senses-science-behind-sensory-loss-and-dementia-risk"
    },
    {
      "title": "Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss (ACHIEVE): a multicentre, randomised, controlled trial in the United States",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10529382/"
    },
    {
      "title": "Hearing aids slow cognitive decline in people at high risk",
      "url": "https://www.nia.nih.gov/news/hearing-aids-slow-cognitive-decline-people-high-risk"
    },
    {
      "title": "Deaf women who use American Sign Language",
      "url": "https://stacks.cdc.gov/view/cdc/30049/cdc_30049_DS1.pdf"
    },
    {
      "title": "Say what? – Melnick Medical Museum",
      "url": "https://melnickmedicalmuseum.com/2015/03/20/say-what/"
    },
    {
      "title": "A collapsible Victorian ear trumpet made of tin made by Atkinson, Union Court, Holborn, London",
      "url": "https://wellcomecollection.org/works/scnw53hm"
    },
    {
      "title": "Experiencing ear trumpets in the Enlightenment",
      "url": "https://works.www.wellcomecollection.org/events/experiencing-ear-trumpets-in-the-enlightenment"
    },
    {
      "title": "Smithsonian Studies in History and Technology",
      "url": "https://www.govinfo.gov/content/pkg/GOVPUB-SI-PURL-gpo21283/pdf/GOVPUB-SI-PURL-gpo21283.pdf"
    },
    {
      "title": "The evolution of cochlear implant technology and its clinical relevance",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4391344/"
    },
    {
      "title": "The cochlear implant restores hearing: Case Study",
      "url": "https://www.nhmrc.gov.au/about-us/resources/impact-case-studies/cochlear-implant-restores-hearing"
    },
    {
      "title": "Premarket Approval (PMA): Nucleus Multichannel Implantable Hearing Prosthesis",
      "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P840024"
    },
    {
      "title": "What is a Cochlear Implant?",
      "url": "https://www.fda.gov/medical-devices/cochlear-implants/what-cochlear-implant"
    },
    {
      "title": "Adding insult to injury: cochlear nerve degeneration after \"temporary\" noise-induced hearing loss",
      "url": "https://pubmed.ncbi.nlm.nih.gov/19906956/"
    },
    {
      "title": "Impaired speech perception in noise with a normal audiogram: No evidence for cochlear synaptopathy and no relation to lifetime noise exposure",
      "url": "https://cdn.vanderbilt.edu/vu-my/wp-content/uploads/sites/583/2017/12/14100603/Guest-et-al.-2018-Hear-Res-Impaired-speech-perception-in-noise-with-a-normal-audiogram-no-evidence-for-cochlear-synaptopathy-and-no-relation-to-lifetime-noise-exposure.pdf"
    },
    {
      "title": "A phase I/IIa safety and efficacy trial of intratympanic gamma-secretase inhibitor as a regenerative drug treatment for sensorineural hearing loss",
      "url": "https://discovery.ucl.ac.uk/10188618/1/s41467-024-45784-0.pdf"
    },
    {
      "title": "Sudden Sensorineural Hearing Loss (SSHL)",
      "url": "https://www.nidcd.nih.gov/health/sudden-deafness?nav=tw"
    },
    {
      "title": "Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21610239/"
    },
    {
      "title": "Hearing aid service delivery approaches for low- and middle-income settings",
      "url": "https://www.who.int/publications/b/71428"
    },
    {
      "title": "WHO issues guidance to improve access to hearing care in low- and middle-income settings",
      "url": "https://www.who.int/news/item/01-03-2024-who-issues-guidance-to-improve-access-to-hearing-care-in-low--and-middle-income-settings"
    }
  ],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}